Individual Preference for Fecal Immunochemical Test Options among Younger Adults: A Discrete Choice Experiment [0.03%]
年轻成人粪便免疫化学试验选项的个人偏好：一项离散选择实验
Kailu Wang,Ho-Man Shum,Carrie Ho-Kwan Yam et al.
Kailu Wang et al.
Objectives: This study aims to quantify the preference of adults below 50 years of age for fecal immunochemical test (FIT) options as screening for colorectal cancer (CRC) and its disparities across different subgroups. ...
Willingness to Pay for Improved Quality of Services from Informal Health Providers in Urban Slums in Nigeria [0.03%]
尼日利亚城市贫民窟居民对改善非正规医疗服务质量的支付意愿
Obinna Onwujekwe,Godwin Uche Ezema,Chukwudi Nwokolo et al.
Obinna Onwujekwe et al.
Introduction: The shortage of formal healthcare providers in urban slums has resulted in the widespread presence of untrained informal healthcare providers (IHPs), who often deliver low-quality services. Integrating these...
Workneh Wondimagegn Azalu,Wudu Temesgen Jemberu,Bihonegn Wodajnew Taye et al.
Workneh Wondimagegn Azalu et al.
Background: Rabies remains a significant threat to both public health and economic stability across many developing countries. The challenge of effectively managing and preventing rabies is compounded by insufficient quan...
Identifying Potential Gaps in Care for Patients with Higher-Risk Myelodysplastic Syndromes in a Large US Health System [0.03%]
在美国大型医疗系统中识别较高风险骨髓增生异常综合征患者护理中的潜在缺口
Kristin J Moore,Nicole M Engel-Nitz,Peter McMahon et al.
Kristin J Moore et al.
Background: Higher-risk myelodysplastic syndromes (HR-MDS) may be difficult to diagnose because patients present with nonspecific signs and symptoms. This can prolong diagnosis, even though disease progression can occur q...
Correction: Cost-Effectiveness of Vedolizumab as a First-Line Advanced Therapy Versus Adalimumab Treatment Sequences for Ulcerative Colitis in Italy [0.03%]
对 vedolizumab 作为溃疡性结肠炎的一线生物制剂疗法与意大利阿达木单抗治疗序列的成本效益研究的更正通知
Jonathan Salcedo,Daniel Hill-McManus,Chloë Hardern et al.
Jonathan Salcedo et al.
Published Erratum
PharmacoEconomics - open. 2025 Aug 19. DOI:10.1007/s41669-025-00596-w 2025
Treatment (as Prevention) Availability and Individuals' Behavior: A Cost-Effectiveness Analysis of Cabotegravir Long-Acting Injectable PrEP [0.03%]
作为预防的治疗可及性与个体行为：卡博特格拉韦长效注射剂作为一种暴露前预防的成本效益分析
J Felipe Montano-Campos,Blythe Adamson
J Felipe Montano-Campos
Background: The US Food and Drug Administration (FDA) has approved long-acting injectable agents for preexposure prophylaxis (PrEP) of human immunodeficiency virus (HIV) infection. These agents are urgently required to en...
Economic Evaluation of Treatment With Trastuzumab Deruxtecan for HER2-Low Advanced or Metastatic Breast Cancer in Previously Treated Patients [0.03%]
治疗HER2低表达晚期或转移性乳腺癌患者的曲妥珠单抗deruxtecan疗法的经济评估
Silvia Fenix-Caballero,Pablo Caleffa-Menendez,Carmen Maria Dominguez-Santana et al.
Silvia Fenix-Caballero et al.
Objectives: This study evaluates the efficiency and budgetary impact of trastuzumab deruxtecan (T-DXd) compared with standard therapy in previously treated HER2-low advanced or metastatic breast cancer, from the perspecti...
Cost-Effectiveness of an Insertable Cardiac Arrhythmia Monitor after Non-ST-Elevation Myocardial Infarction in the UK [0.03%]
英国非ST段抬高型心肌梗死后植入式心脏监测仪的成本效益分析
Amy Dymond,E Barker,N Tsitiridis et al.
Amy Dymond et al.
Background and objectives: Patients surviving a non-ST-elevation myocardial infarction (NSTEMI) have an elevated risk of future major adverse cardiovascular events (MACE), which can be mitigated through long-term cardiac ...
Economic Evaluation of Lecanemab for Early Symptomatic Alzheimer's Disease in South Korea [0.03%]
韩国早期症状性阿尔茨海默病患者使用莱卡奈单抗的经济学评价
Seungyeon Shin,Maryanne Kim,Song Hee Hong
Seungyeon Shin
Background/objectives: Alzheimer's disease (AD) exerts a considerable economic burden on South Korea's aging population. Lecanemab, an amyloid-targeting therapy, has demonstrated efficacy in mitigating cognitive decline i...
Missing Pieces of the Puzzle to Address Market Failures for Antibiotics: Delinked Payment Systems and Insurance Value [0.03%]
应对抗生素市场失灵的缺失环节：解绑支付体系与价值险%HIT2019国际肿瘤创新大会
Neil Hawkins,Adrian Towse,Amanda Adler
Neil Hawkins
Too few companies develop new antibiotics because of the threat of market failure. To address this, a 'delinked' payment, distinct from the usual payment model for drugs, makes payments to manufacturers that do not depend on the volume of a...